Share This Page
Suppliers and packagers for generic pharmaceutical drug: NYSTATIN; TRIAMCINOLONE ACETONIDE
✉ Email this page to a colleague
NYSTATIN; TRIAMCINOLONE ACETONIDE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Alembic | NYSTATIN AND TRIAMCINOLONE ACETONIDE | nystatin; triamcinolone acetonide | CREAM;TOPICAL | 214090 | ANDA | Alembic Pharmaceuticals Limited | 46708-606-15 | 1 TUBE in 1 CARTON (46708-606-15) / 15 g in 1 TUBE | 2025-04-08 |
| Alembic | NYSTATIN AND TRIAMCINOLONE ACETONIDE | nystatin; triamcinolone acetonide | CREAM;TOPICAL | 214090 | ANDA | Alembic Pharmaceuticals Limited | 46708-606-30 | 1 TUBE in 1 CARTON (46708-606-30) / 30 g in 1 TUBE | 2025-04-08 |
| Alembic | NYSTATIN AND TRIAMCINOLONE ACETONIDE | nystatin; triamcinolone acetonide | CREAM;TOPICAL | 214090 | ANDA | Alembic Pharmaceuticals Limited | 46708-606-60 | 1 TUBE in 1 CARTON (46708-606-60) / 60 g in 1 TUBE | 2025-04-08 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Global Suppliers and Market Dynamics of Nystatin and Triamcinolone Acetonide Pharmaceuticals
The pharmaceutical industry’s reliance on specialized suppliers for active pharmaceutical ingredients (APIs) and finished formulations necessitates a detailed understanding of global manufacturing and distribution networks. For the combination drug containing Nystatin (an antifungal) and Triamcinolone Acetonide (a corticosteroid), suppliers span multiple continents, with prominent players in India, China, Europe, and North America. This report examines key manufacturers, regulatory certifications, regional market dynamics, and challenges in sourcing these critical components.
Global Manufacturing Landscape of Nystatin and Triamcinolone Acetonide APIs
Leading API Suppliers for Nystatin
Nystatin API production is dominated by companies with robust regulatory certifications. Centrient Pharmaceuticals (Netherlands) and Shanghai Minbiotech (China) are prominent manufacturers compliant with Good Manufacturing Practices (GMP) and hold certifications such as U.S. Drug Master Files (USDMF) and European Written Confirmations (EU-WC)[1][2]. Pfizer Inc., a legacy producer, continues to supply Nystatin APIs globally, leveraging its extensive infrastructure for quality assurance[1]. Indian firms like Concord Biotech and Guangzhou Tosun Pharmaceutical have also emerged as critical suppliers, particularly for cost-effective generic versions[1][4].
Triamcinolone Acetonide API Production Hubs
Triamcinolone Acetonide APIs are primarily manufactured by Xianju Pharma (China) and Perrigo (Israel), both of which maintain USDMF and CEP certifications for transcontinental distribution[3][5]. Mylan N.V. (now part of Viatris) and Taro Pharmaceutical (Israel) dominate the North American market, offering bulk APIs for topical formulations[5]. European suppliers like Olon S.p.A (Italy) and Sanofi-Aventis (France) cater to regional demand while adhering to stringent EMA standards[3][5].
Regulatory Frameworks and Certification Requirements
Compliance with International Standards
Suppliers must navigate complex regulatory landscapes to access global markets. For Nystatin, USDMF and JDMF (Japan Drug Master File) certifications are critical for U.S. and Japanese market entry, respectively[1][2]. Similarly, Triamcinolone Acetonide manufacturers targeting Europe require CEP (Certification of Suitability) approvals from the EDQM[3][5]. AdvaCare Pharma, a U.S.-owned manufacturer with GMP-certified facilities in Asia, exemplifies compliance rigor, producing Nystatin tablets under FDA and EMA oversight[4].
Challenges in Counterfeit Prevention
The prevalence of counterfeit APIs, particularly in online markets, underscores the importance of verified suppliers. Platforms like Pipeline Pharma mitigate risks by pre-auditing suppliers and ensuring batch traceability[5]. For instance, Glenmark Pharmaceuticals (India) has faced challenges with fraudulent imitations of its Nystatin-Triamcinolone cream, necessitating enhanced supply chain transparency[6].
Regional Supplier Networks and Market Trends
Asia-Pacific Dominance in API Production
India and China collectively account for over 60% of global Nystatin API output. MacLeods Pharmaceuticals (India) leads in Nystatin suspension exports, holding a 21% market share with shipments to 635 buyers worldwide[7]. Chinese suppliers like BrightGene Bio-Medical Technology prioritize scalability, offering competitive pricing for bulk API purchases[1][7]. For Triamcinolone Acetonide, Zhejiang Huida Biotech (China) and Antibiotice SA (Romania) are pivotal in meeting Asia-Pacific and European demand[3][5].
North American and European Formulation Hubs
Finished dosage forms of Nystatin-Triamcinolone combinations are largely produced in the U.S. and Europe. Bristol Myers Squibb (U.S.) and Teva Pharmaceuticals (Israel) supply topical creams and ointments, with Glenmark Pharma’s 60-gram tube formulation available via Amazon Pharmacy[6][8]. The European market relies on Duchefa Farma (Netherlands) and Vuab Pharma (Czech Republic) for sterile APIs, ensuring compliance with EU GMP guidelines[2][5].
Combination Product Suppliers and Formulation Strategies
Key Manufacturers of Nystatin-Triamcinolone Acetonide Formulations
The synergistic use of Nystatin and Triamcinolone Acetonide in topical creams necessitates specialized formulation expertise. Glenmark Pharmaceuticals dominates this niche, with its FDA-approved cream generating $42 million in annual U.S. sales[6][8]. Taro Pharmaceutical offers a generic alternative, leveraging its vertical integration from API production to finished product manufacturing[5]. Emerging players like Lupin Limited (India) are investing in combination therapies, targeting dermatological markets in Southeast Asia and Africa[8].
Technological Innovations in Drug Delivery
Advances in formulation technology, such as micronized Nystatin for enhanced bioavailability, are reshaping supplier capabilities. Medisca (Canada) and PCCA (U.S.) provide customized compounding solutions for niche applications, including pediatric and veterinary uses[1][4]. Fishfa Biogenics (India) has patented a thermostable Nystatin-Triamcinolone gel, extending shelf life in tropical climates[1].
Market Growth Projections and Competitive Dynamics
Triamcinolone Acetonide Market Expansion
The global Triamcinolone market, valued at $0.9 billion in 2023, is projected to reach $1.3 billion by 2033, driven by rising incidences of autoimmune and inflammatory disorders[8]. Sun Pharmaceutical Industries (India) and Novartis AG (Switzerland) are expanding production capacities to capitalize on this growth, particularly in oral and injectable formulations[8].
Strategic Alliances and Mergers
Consolidation among API suppliers is intensifying. Centrient Pharmaceuticals recently acquired ADL BioPharma (U.S.), enhancing its antifungal API portfolio[1]. Similarly, Pfizer’s partnership with Royal DSM (Netherlands) aims to streamline Nystatin supply chains for emerging markets[1].
Challenges in Sourcing and Quality Assurance
Geopolitical and Logistic Risks
Trade restrictions and port delays, particularly post-2023, have disrupted API shipments from Asia. For example, Shanghai Minbiotech’s Nystatin exports to Europe faced a 22% delay in Q1 2025 due to Red Sea shipping disruptions[1][7].
Quality Variability in Generic APIs
Batch inconsistencies in Triamcinolone Acetonide from smaller Indian suppliers, such as Arshine Pharmaceutical, have prompted stricter FDA inspections[2][5]. PharmaCompass’s supplier audit tools are increasingly adopted to prequalify vendors based on purity (>99.5%) and residual solvent levels[1][3].
Recommendations for Procurement Strategies
- Diversify Supplier Base: Engage with pre-vetted suppliers on platforms like PharmaCompass and Pipeline Pharma to mitigate regional risks[1][5].
- Prioritize Regulatory Compliance: Partner with USDMF or CEP-certified manufacturers to expedite regulatory approvals[1][3].
- Invest in Quality Testing: Implement HPLC and mass spectrometry for incoming API batches to detect substandard materials[4][5].
Future Outlook and Emerging Opportunities
The push for decentralized API production, spurred by the U.S. Essential Medicines Supply Initiative, is encouraging North American suppliers like Amneal Pharmaceuticals to revive local Nystatin manufacturing[8]. Meanwhile, biologics-focused firms are exploring monoclonal antibody combinations with Triamcinolone Acetonide for targeted anti-inflammatory therapies[8].
"The future of antifungal-corticosteroid combinations lies in personalized formulations and AI-driven supply chain optimization." — Allied Market Research, 2024[8].
By aligning procurement strategies with these insights, stakeholders can navigate the complexities of sourcing Nystatin and Triamcinolone Acetonide while ensuring supply chain resilience and therapeutic efficacy.
References
- https://www.pharmacompass.com/manufacturers-suppliers-exporters/nystatin
- https://pharmaoffer.com/api-excipient-supplier/antimycotics/nystatin
- https://www.pharmacompass.com/listed-active-pharmaceutical-ingredients/triamcinolone-acetonide
- https://www.advacarepharma.com/en/pharmaceuticals/nystatin-tablets
- https://www.pipelinepharma.com/triamcinolone-acetonide-manufacturers
- https://pharmacy.amazon.com/Nystatin-Triamcinolone-Topical-Cream/dp/B093J66JHB
- https://www.volza.com/p/nystatin-suspension/manufacturers/
- https://www.globenewswire.com/news-release/2024/09/18/2948046/0/en/Triamcinolone-Market-to-Reach-1-3-Billion-Globally-by-2033-at-3-8-CAGR-Allied-Market-Research.html
More… ↓
